The principle of momentum investing—though contrary to the traditional wisdom of buying low and selling high—suggests that investors can profit by buying rising stocks and selling them before they decline. As a result, momentum is typically favored in short-term and active trading stra.... |
Good MorningEquity markets started the week on weakened footing following the start of Trump's tariffs. However, the news isn't all bad. Investors bought the early morning weakness, leaving the S&P 500 well off the session's lows by the day's end. The takeaway is that Trump's tariffs will likely cause market volatility, but the upward trend is intact, and new all-time-high index prices are possible.
Earnings will help drive the action this week. After the Monday close, an after-hours report from Palantir underscored the impact of AI on business, leading its stock to a 15% gain. Other critical reports include Advanced Micro Devices, Amazon, and Google, all expected to report solidly.
Critical economic data is also expected this week. Monthly labor data are due, including the ADP, Challenger, JOLTs, and non-farm payroll reports. The consensus is that the data align with trends, including steady job creation, low unemployment, and rising wages. Featured: Sell these "safe" blue chips immediately (Ad) 
| Healthcare | |
The principle of momentum investing—though contrary to the traditional wisdom of buying low and selling high—suggests that investors can profit by buying rising stocks and selling them before they decline. As a result, momentum is typically favored in short-term and active trading stra... Read the Full Story |
| From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
| Markets | |
Starting small is usually good advice when beginning a new endeavor. If you’re trying to get back in shape, a quick run or light workout is a better starting point than a marathon. However, that logic is counterintuitive when it comes to stocks. Bigger stocks tend to be safer and less volati... Read the Full Story |
| Consumer Discretionary | |
Insider buying was solid in January, including dividend-paying names like Lakeland Industries (NASDAQ: LAKE), York Water (NASDAQ: YORW), and RLI Corp (NYSE: RLI). These stocks are not only the most bought dividend stocks insiders bought but the most bought for the month, news that raises the quest... Read the Full Story |
| From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
| Consumer Staples | |
The Wall Street Journal pointed out a peculiar new trend on social media, where influencers are not showcasing their lavish purchases but rather going the opposite route, embracing a “No Buy” trend. Consumers are tired of inflation and lofty credit card interest rates and have deemed 2... Read the Full Story |
| Healthcare | |
Teva Pharmaceuticals Industries Ltd (NYSE: TEVA) is the world's largest generic drug maker, with over 500 generic and biosimilar treatments in its broad portfolio. The medical sector giant also has a line of branded drugs driving growth.
Its specialty medicines address specific conditions, incl... Read the Full Story |
| From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
| Finance | |
Three S&P 500 Index constituents, as well as one of the world’s biggest names in oil and gas, are raising dividends as 2025 gets started. The firm not in the S&P 500 also announced billions in new buyback authorization. All dividend yield and return metrics use prices as of the Jan. ... Read the Full Story |
| Consumer Staples | |
Global consumer products manufacturer Proctor & Gamble Co. (NYSE: PG) posted upbeat earnings in its fourth quarter of 2024.
The consumer staples sector leader sells well-known grooming, baby, personal care, and hygiene products under brands like Pampers, Luvs, Bounce, Downy, Gain, Tide, Bo... Read the Full Story |
| Markets | |
One of the top-performing sectors YTD has been financials, with the popular financial ETF, Financial Select Sector SPDR (NYSEARCA: XLF), already up 6.5% as of Friday’s close. Conversely, one of the sectors that outperformed for the first three quarters of last year, utilities, represented by... Read the Full Story |
| Consumer Discretionary | |
The 2024 holiday shopping season was a robust one. However, January has been nicknamed 'Returnuary' after the age-old tradition of returning products to retailers every year. The National Retail Federation (NRF) estimates a 17% return rate for all U.S. merchandise this year, which is equal to $890... Read the Full Story |
| Industrials | |
With a market capitalization of $265 million, Palladyne AI Corp. (NASDAQ: PDYN) remains a small software firm. However, its massive growth in the last year has provided it momentum far outpacing some of the trendiest larger companies—NVIDIA Corp.'s (NASDAQ: NVDA) 103% return in the year le... Read the Full Story |
| Tuesday's Early Bird Stock Of The Day CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island. | Should I Buy CVS Health Stock? CVS Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of CVS Health was last updated on Wednesday, August 26, 2026 at 6:18 PM.
CVS Health Bull Case -
CVS Health Co. recently reported strong earnings, with an EPS of $2.58, significantly exceeding analysts' expectations, indicating robust financial performance.
-
The company has shown a year-over-year revenue increase of 7.3%, reflecting its growth potential and ability to expand its market share.
-
CVS Health Co. has a solid dividend yield of approximately 2.8%, providing investors with a steady income stream, which is attractive for income-focused investors.
-
Analysts have a consensus rating of "Moderate Buy" for CVS Health Co., with many firms raising their price targets, suggesting positive future performance and investor confidence.
-
The current stock price is around $107.17, which is considered reasonable given the company's strong fundamentals and growth prospects.
CVS Health Bear Case -
The company's net margin is relatively low at 1.18%, which may indicate challenges in profitability compared to competitors.
-
CVS Health Co. has a dividend payout ratio of 70.37%, suggesting that a significant portion of earnings is being distributed as dividends, which could limit reinvestment in growth opportunities.
-
Despite positive earnings, the healthcare sector can be volatile and subject to regulatory changes, which may impact CVS Health Co.'s operations and profitability.
-
There is increasing competition in the pharmacy and healthcare market, which could pressure CVS Health Co.'s market position and margins.
-
Recent upgrades from analysts may lead to inflated expectations, and if the company fails to meet these, it could result in a decline in stock price.
| | View Today's Stock Pick |
|
| |
|
|
